TIMP1 and cancer: Trabectedin has been shown to have antiangiogenic properties in several preclinical studies by activation of TIMP1 (tissue inhibitor of metalloproteinase (1) and TIMP2 (tissue inhibitor of metalloproteinase (2) as well as exerting multimodal targeting of other cancer signaling pathways 41, 42, 43.